Retuning the immune system: the future of type 1 diabetes therapy?
Strategies that restore immune tolerance are attracting growing interest in their potential to advance the treatment of type 1 diabetes beyond lifelong insulin therapy.
Jones
Dan
D
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D010957:Plasmids / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D011384:Proinsulin / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D007004:Hypoglycemic Agents; D007328:Insulin; D011384:Proinsulin